Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc. (AVIR) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · AVIR · as of Sep 30, 2025
Ownership Breakdown
118
Institutional Holders
▲ 13 vs Q2
$154.17M
Total Inst. Value
▼ $35.52M vs Q2
80.03M
Shares Outstanding
freeFloat 75.26%
53.17M
13F Shares Held
▲ 476,821 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
AVIR largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BLACKROCK, INC. pharmaceutical preparations | 8.46M | 10.10% | 10.10% | $24.53B | Nov 12, 2025 | ▼ 209.3K |
BML CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 7.47M | 8.92% | 8.92% | $21.67B | Nov 10, 2025 | ▼ 135.8K |
FMR LLC pharmaceutical preparations | 5.82M | 6.95% | 6.95% | $16.89B | Nov 13, 2025 | ▲ 103.0K |
TANG CAPITAL MANAGEMENT LLC pharmaceutical preparations | 4.83M | 5.76% | 5.76% | $14.00B | Nov 14, 2025 | ▼ 63.0K |
VANGUARD GROUP INC pharmaceutical preparations | 4.71M | 5.62% | 5.62% | $13.66B | Nov 7, 2025 | ▼ 177.9K |
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC pharmaceutical preparations | 2.49M | 2.97% | 2.97% | $7.21B | Nov 14, 2025 | — held |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 1.90M | 2.27% | 2.27% | $5.51B | Nov 12, 2025 | ▼ 25.8K |
STATE STREET CORP pharmaceutical preparations | 1.78M | 2.13% | 2.13% | $5.17B | Nov 14, 2025 | ▲ 7.6K |
DIMENSIONAL FUND ADVISORS LP pharmaceutical preparations | 1.54M | 1.84% | 1.84% | $4.47B | Nov 12, 2025 | ▲ 129.5K |
RENAISSANCE TECHNOLOGIES LLC pharmaceutical preparations | 1.23M | 1.47% | 1.47% | $3.56B | Nov 13, 2025 | ▼ 6.2K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
23
Increased
+2.11M shares1
New Positions
first time holders17
Decreased
−1.04M shares0
Sold Out
fully exitedNet shares change (top 50)
+1.07M
+2.11M / −1.04M
Net new holders
+7
1 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
AVIR insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
14
Buy transactions
13
Sell transactions
1.08
Buy/Sell ratio
$1M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Murphy Polly A. director | May 18, 2026 | Purchase | 6,100 | $4.17 | $25.4K | 92.1K | Form 4 ↗ |
Murphy Polly A. director | May 18, 2025 | Purchase | 6,100 | $4.17 | $25.4K | 92.1K | Form 4 ↗ |
Horga Maria Arantxa Chief Medical Officer | Jan 31, 2026 | Award | 173,500 | $4.24 | $735.6K | 173.5K | Form 4 ↗ |
Horga Maria Arantxa Chief Medical Officer | Jan 31, 2026 | Tax Withhold | 16,073 | $4.24 | $68.1K | 96.1K | Form 4 ↗ |
Vavricka John Chief Commercial Officer | Jan 31, 2026 | Award | 119,520 | $4.24 | $506.8K | 119.5K | Form 4 ↗ |
Vavricka John Chief Commercial Officer | Jan 31, 2026 | Tax Withhold | 11,570 | $4.24 | $49.1K | 82.6K | Form 4 ↗ |
Hammond Janet MJ Chief Development Officer | Jan 31, 2026 | Award | 177,000 | $4.24 | $750.5K | 177.0K | Form 4 ↗ |
Hammond Janet MJ Chief Development Officer | Jan 31, 2026 | Tax Withhold | 14,136 | $4.24 | $59.9K | 127.7K | Form 4 ↗ |
Corcoran Andrea See Remarks | Jan 31, 2026 | Tax Withhold | 16,104 | $4.24 | $68.3K | 763.6K | Form 4 ↗ |
Corcoran Andrea See Remarks | Jan 31, 2026 | Award | 180,000 | $4.24 | $763.2K | 180.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Atea Pharmaceuticals, Inc. (AVIR) is primarily owned by institutional investors, who hold approximately 66.4% of total shares outstanding. Company insiders own approximately 24.74%, while retail and public investors account for the remaining 8.83%.
The largest institutional shareholder of Atea Pharmaceuticals, Inc. is BLACKROCK, INC., holding approximately 8.46 million shares — equal to 10.10% of outstanding shares — as of September 30, 2025.
A total of 118 institutional investors currently hold AVIR stock, with a combined institutional value of approximately $154,170,449 as of the most recent 13F filing period.
Frequently asked questions
AVIR ownershipAtea Pharmaceuticals, Inc. (AVIR) is primarily owned by institutional investors, who hold approximately 66.4% of shares. The largest shareholder is BLACKROCK, INC. with a 10.10% stake. Company insiders hold 24.74%. Data sourced from SEC Form 13F as of September 30, 2025.